Jonathan L French

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi Bayesian methods for a three-state model for rodent carcinogenicity studies
    Jonathan L French
    Biostatistics, Pfizer Global Research and Development, 50 Pequot Avenue, New London, Connecticut 06320, USA
    Biometrics 58:906-16. 2002
  2. ncbi Generalized additive models for cancer mapping with incomplete covariates
    Jonathan L French
    Biostatistics, Global Research and Development, Pfizer, Inc, 50 Pequot Avenue, New London, CT 06320, USA
    Biostatistics 5:177-91. 2004
  3. ncbi Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures
    Karthik Venkatakrishnan
    Department of Clinical Pharmacology, Pfizer Global Research and Development, Groton, Connecticut 06340, USA
    Drug Metab Dispos 35:1341-9. 2007
  4. ncbi Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation
    Jae Eun Ahn
    Global Pharmacometrics, Pfizer Inc, 50 Pequot Ave MS 6025 A2249, New London, CT 06320, USA
    J Pharmacokinet Pharmacodyn 37:179-201. 2010

Detail Information

Publications4

  1. ncbi Bayesian methods for a three-state model for rodent carcinogenicity studies
    Jonathan L French
    Biostatistics, Pfizer Global Research and Development, 50 Pequot Avenue, New London, Connecticut 06320, USA
    Biometrics 58:906-16. 2002
    ..We implement the model by analyzing data from a National Toxicology Program chronic rodent bioassay...
  2. ncbi Generalized additive models for cancer mapping with incomplete covariates
    Jonathan L French
    Biostatistics, Global Research and Development, Pfizer, Inc, 50 Pequot Avenue, New London, CT 06320, USA
    Biostatistics 5:177-91. 2004
    ..We illustrate our method through an analysis of cancer incidence data from Cape Cod, Massachusetts. These analyses demonstrate that standard complete-case methods can yield biased estimates of the spatial variation of cancer risk...
  3. ncbi Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures
    Karthik Venkatakrishnan
    Department of Clinical Pharmacology, Pfizer Global Research and Development, Groton, Connecticut 06340, USA
    Drug Metab Dispos 35:1341-9. 2007
    ....
  4. ncbi Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation
    Jae Eun Ahn
    Global Pharmacometrics, Pfizer Inc, 50 Pequot Ave MS 6025 A2249, New London, CT 06320, USA
    J Pharmacokinet Pharmacodyn 37:179-201. 2010
    ..Models that included only treatment arm-level random effects were not superior in any scenario...